DIA
PCRX icon

Dana Investment Advisors’s Pacira BioSciences PCRX Stock Holding History

Dana Investment Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-9,345
Closed -$273K – 531
2024
Q1 		$273K Sell
9,345
-1,100
-11% -$33.8K 0.01% 492
2023
Q4 		$352K Sell
10,445
-500
-5% -$14.6K 0.02% 361
2023
Q3 		$336K Hold
10,945
– – 0.02% 353
2023
Q2 		$439K Sell
10,945
-17,880
-62% -$739K 0.02% 337
2023
Q1 		$1.18M Sell
28,825
-950
-3% -$37.8K 0.06% 215
2022
Q4 		$1.15M Sell
29,775
-5,774
-16% -$281K 0.06% 210
2022
Q3 		$1.89M Sell
35,549
-2,358
-6% -$131K 0.11% 131
2022
Q2 		$2.21M Buy
+37,907
New +$2.48M 0.11% 128

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dana Investment Advisors's PCRX Position: Q2 2024 in Review

Dana Investment Advisors sold out of Pacira BioSciences (PCRX) in Q2 2024, closing a stake of 9,345 shares — an estimated $273K sold.

Dana Investment Advisors first reported a position in PCRX in Q2 2022 and held it in 8 quarters. The position peaked at $2.21M in Q2 2022. 280 funds tracked by Wall St. Rank hold PCRX as of Q2 2024.

  • Dana Investment Advisors reported no remaining Pacira BioSciences position as of Q2 2024 after selling out during the quarter.
  • Dana Investment Advisors sold 9,345 Pacira BioSciences shares in Q2 2024, an estimated $273K.
  • Dana Investment Advisors first reported a position in Pacira BioSciences in Q2 2022 and held it in 8 quarters.
  • Dana Investment Advisors's Pacira BioSciences position peaked at $2.21M in Q2 2022.
  • 280 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2024.

Based on Dana Investment Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.